checkAd

     694  0 Kommentare Thriving Global Medical Device Industry Projected to Top $400 Billion by 2023

    PALM BEACH, Florida, December 19, 2018 /PRNewswire/ --

    Financialnewsmedia.com News Commentary 

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Johnson & Johnson!
    Long
    137,16€
    Basispreis
    1,14
    Ask
    × 12,16
    Hebel
    Short
    162,13€
    Basispreis
    1,19
    Ask
    × 11,65
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    While many medical industry professionals know very well the reality that life expectancy and as well as emerging economies' are increasing expenditures on healthcare, one glaring fact persists of the obvious need for advanced medical devices are more important than ever. As a result, a prime example could be the cardiology marketplace within the medical devices industry that is being transformed by advancements in Electrocardiographic technologies. High technological adoption in the U.S. coupled with increasing research activities pertaining to development of new cardiac technology and devices has positively impacted market growth. In a recent study released by ResearchAndMarkets.com, the global medical device market is expected to reach an estimated $409.5 Billion by 2023, and it is forecast to grow at a CAGR of 4.5% from 2018 to 2023. Major factors for the growth in the medical devices industry are aging population, technological development, prevalence of cardiovascular diseases as well as other chronic conditions and maladies. Active healthcare stocks in news today include: BioSig Technologies, Inc. (NASDAQ: BSGM), Medtronic plc (NYSE: MDT), DexCom, Inc. (NASDAQ: DXCM), Abbott Laboratories (NYSE: ABT), Johnson & Johnson (NYSE: JNJ).

    BioSig Technologies, Inc. (NASDAQ: BSGM) BREAKING NEWS - BioSig Technologies, a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has appointed Mrs. MaryAnn Edzards as Senior Director - Account Manager.

    Mrs. Edzards brings to the Company over 10 years of experience in electrophysiology (EP), including six years at Biosense Webster, a Johnson & Johnson company. Most recently, she served as New Technology Education Manager, a role, in which she was responsible for all internal and external marketing and training programs for two global product launches. Mrs. Edzards facilitated training of over 300 field and in-house employees and delivered impactful training modules for complex technologies through virtual and live classroom environments. She brings to BioSig extensive experience in converting Voice of Customer feedback into commercially valuable solutions. Mrs. Edzards is a holder of numerous Johnson & Johnson awards, including 2016 Standards of Leadership Award and 2017 Gold Encore Award from Commercial Marketing.

    Seite 1 von 4



    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Thriving Global Medical Device Industry Projected to Top $400 Billion by 2023 PALM BEACH, Florida, December 19, 2018 /PRNewswire/ - Financialnewsmedia.com News Commentary  While many medical industry professionals know very well the reality that life expectancy and as well as emerging economies' are increasing expenditures on …

    Schreibe Deinen Kommentar

    Disclaimer